Q-omics provides the consensus-scored SESTD1 profile across patient tissues and cancer cell-line models. SESTD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SESTD1 is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, SESTD1 RNA expression shows 20,634 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where SESTD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SESTD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SESTD1 survival associations across molecular data types. SESTD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SESTD1 RNA expression–survival associations across cancer types. High SESTD1 expression shows unfavorable associations in MESO, LIHC, ACC and CESC, but favorable associations in KIRC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SESTD1 RNA expression.
This table summarizes SESTD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SESTD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SESTD1 shows lower tumor expression in LUSC, LUAD and THCA and higher tumor expression in LIHC, KIRP and CHOL. The LIHC box plot shows higher SESTD1 RNA expression in tumor versus normal tissue (log2 FC = +1.128, t-test p < 0.001).
This table shows molecular features associated with SESTD1 in patient tissues and cancer cell lines. In patient samples, SESTD1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SESTD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
